Dermsquared’s Post

Idiopathic Osteoarthritis: Unraveling the Enigma of Joint Degeneration Learn the potential contributing factors, clinical manifestations, diagnostic challenges, and contemporary management approaches. https://lnkd.in/gRUmSAGb #osteoarthritis #osteoarthritistreatment #osteoarthritissupport #osteoarthritiscare #osteoarthritisawareness #osteoarthritisknee #osteoarthritiship #osteoarthritispain #osteoarthritiscare

In their NCCIH lab, Dr. Alex Chesler and his team are probing the ways in which our brains detect and process different sensations, including both pleasant and painful ones. Improving knowledge of these basic mechanisms may help researchers develop new therapeutic approaches for treating acute and chronic pain. https://go.nih.gov/pWEwQG7 #NIHPainProgress #PainAwarenessMonth

📹CLINICAL CASE COLLECTIVE: Gain comprehensive insights into the evolving treatment landscape, nonsteroidal therapies, and current data trends. Delve into a detailed case study highlighting treatment selection and shared decision-making for better outcomes. Stay informed on the latest in psoriasis care: https://ow.ly/QgXl50TGeVi

Ketamine therapy invites you on an inward journey, transforming internal exploration into a powerful healing process. With closed eyes, patients discover profound self-healing and insights. Explore the therapeutic potential within. #InnerWellness #ResetKetamine

Join Shirley Ryan AbilityLab and Prakash Jayabalan MD, PhD this week for our May 16 #webinar. Currently, individuals with knee osteoarthritis (OA) are treated by a ‘one-size fits all’ approach and many clinicians cannot tell which patients will benefit most from which treatment. An exciting, novel approach to treating OA is connecting information about a person’s biologic makeup to their clinical symptoms. https://lnkd.in/gBvM-U-7

This recently published Review Article discusses the essential nature of RBP-directed post-transcriptional control in both driving the evolution of LSCs and maintaining their pathogenic function, showcasing that RBPs hold incredible potential as targets for LSC-selective therapies 👉https://bit.ly/3TyJvg6

Benzodiazepines are known to lead to dependency quickly and have numerous side effects. Long-term use is not recommended. However, if there is a long-term prescription, the goal should be to end therapy with these tranquilizers. However, discontinuation could have unexpected consequences, as US researchers reported in JAMA Network Open. In a registry study, patients who discontinued benzodiazepines after long-term therapy had an increased risk for death in the following 12 months. Whether there is a causal relationship between discontinuation of therapy and increased mortality rate or whether it is just the temporal coincidence of two phenomena cannot be answered by the study.

Be a Part of Hypertension Research: Join Our Trials! 🔬 Are you curious about how clinical trials work? Participating in our hypertension research not only provides you with expert care but also contributes to the development of better treatment options for others. 🌟 Interested in making a difference? Contact us to learn more about how you can join our clinical trials today! #ClinicalTrials #HypertensionResearch #BetterTogether #JoinOurStudy #BePartOfTheChange

Myotonic Dystrophy Type 1 (DM1) is a rare, inherited, multisystemic disorder. It causes progressive muscle weakness and myotonia (delayed muscle relaxation). There are currently no approved treatments that target the root cause of DM1. But an experimental drug is showing promising signs. Delpacibart Etedesiran (del-desiran) is designed to target cells affected by DM1. The drug was reported to achieve consistent, durable improvements in myotonia, muscle strength, and mobility. Learn more about this investigational treatment in the Emerging Health Care Innovation Brief: https://hubs.la/Q02tSLpM0 #myotonicdystrophy #myotonicdystophytype1 #rarediseases #patientcare #healthcare #innovation #horizonscanning

In essence, a placebo is an ineffective medication or therapy that has no therapeutic benefit. They are frequently employed as a control group in clinical experiments, allowing comparisons with the medication or therapy under investigation. But why do they matter so much? Because of placebo, researchers can distinguish between the psychological benefits that stem from patients' expectations and the drug's true therapeutic efficacy by comparing a new drug's effects to those of a placebo. Surprisingly, though, people recover only because they think they are getting treatment. The placebo effect is a phenomenon that strengthens the link between the brain and body and how they function in tandem. It highlights how our expectations and beliefs can affect the way our health turns out. It's crucial to remember that while the placebo effect is intriguing and provides insight into the mind-body link, it doesn't imply that placebos can take the place of all treatments. Treatment for many illnesses still involves targeted, proactive medical measures. The idea that placebos are merely "fake treatments" has to be dispelled. In actuality, they provide insightful perspectives into the depths of the human brain and the amazing interaction between our bodies and minds. This field forces us to rethink how we think about medicine, healing, and the power of belief as we continue to study it. #ClinicalResearch #PlaceboEffect #MindBodyConnection